Combined 5-Fluorouracil (NSC-19893) and Hydrazine-1- Acetyl-2-Picolinoyl (NSC-68626) Therapy in the Treatment of Adenocarcinoma of the Stomach and Colon and Carcinoid

Accounting for All Patients in Waterfall Plots

J Moon;M LeBlanc;M Othus JCO Clinical Cancer Informatics Apr;5:414-420

PMid: PMID33830787 | PMC number: PMC8240789

RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis

S Litiere;G Isaac;E DeVries;J Bogaerts;A Chen;J Dancey;R Ford;S Gwyther;O Hoekstra;E Huang;N Lin;Y Liu;S Mandrekar;LH Schwartz;L Shankar;P Therasse;L Seymour;RECIST Working Group Journal of Clinical Oncology May 1;37(13):1102-1110; Mar 12:JCO1801100. doi: 10.1200/JCO.18.01100. [Epub ahead of print]

PMid: PMID30860949 | PMC number: PMC6494357

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (SWOG S0438) [PMID:22228638; PMC3481165; NIHMSID410808;]

K Margolin;J Moon;L Flaherty;C Lao;C Lao;M Othus;JA Sosman;J Kirkwood;V Sondak Clinical Cancer Research 18(4):1129-1137;

PMid: PMID22228638 | PMC number: PMC3481165

Benchmarks for evaluating phase II clinical trials in stage IV melanoma: the recent SWOG experience

V Sondak;M Othus;L Flaherty;B Redman;J Moon;K Margolin;C Lao;W Carson;A Ribas International Melanoma Congress, abstract 50; 8th Annual Meeting, Nov 9-11, 2011, Tampa, Fl; oral presentation

Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group trial S0438

K Margolin;J Moon;L Flaherty;C Lao;W Akerley;J Sosman;J Kirkwood;V Sondak Journal of Clinical Oncology 28:7s (suppl; abstr 8502); ASCO 2010 Meeting; oral